Search Results for "Immunotherapy"

In this interactive case study, you will prepare for a tumor board discussion that will determine whether your patient is a candidate for biomarker testing and eligible for biomarker-directed therapy.

In this interactive case study, you will be constructing a pedigree and learning about red flags that would necessitate referral to a genetics professional.

Caring for patients being treated for relapsed/refractory multiple myeloma (MM) presents unique challenges. Recognizing the signs of relapse is essential, as is understanding adverse events associated with common treatment regimens for MM over time. Learn about the many considerations for treating MM in a relapsed/refractory setting, including possible treatment side effects and patient education. This case focuses on understanding risks associated with certain treatments, and possible alternative treatments.

Cancer care across the healthcare continuum has been revolutionized by advances in the understanding and application of genomics. The paradigm shift to biomarker-driven treatment decisions is a large step toward achieving precision oncology, which is the use of tumor-specific information, like genomic information, to inform cancer care.

Radiation oncology requires you to possess a highly specialized knowledge base. In this program, you’ll learn how radiobiology is used to treat various forms of cancer, and recognize the risk factors and nursing interventions for the common side effects of treatment.

High-risk anti-cancer medications, such as chemotherapy, immunotherapy and targeted therapy require a consistent and standardized approach to handling, ordering, preparing, dispensing, and administering to ensure patient and provider safety.

Using two agents that target two different receptors more than doubles length of survival for advanced melanoma than a single agent alone, researchers reported at the 2021 American Society of Clinical Oncology annual meeting.

Patients with uveal melanoma who were treated with tebentafusp, an investigational immunotherapy, lived a median 5.7 months longer than those in comparison groups, researchers reported in study findings presented at the American Association for Cancer Research 2021 annual meeting.

Completing up to a year of pembrolizumab immunotherapy after surgical resection of stage IIB or IIC melanoma decreases patients’ risk for disease recurrence or death by 35%, according to study findings presented at the European Society for Medical Oncology 2021 annual meeting. The new findings led the U.S. Food and Drug Administration to expand its approval of pembrolizumab to use as adjuvant therapy in both adults and children aged 12 and older with early-stage melanoma.